Cargando…

Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice

The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranas...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Mary C., Jones, Taff, Kenney, Richard T., Barnard, Dale L., Burt, David S., Lowell, George H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115497/
https://www.ncbi.nlm.nih.gov/pubmed/17640780
http://dx.doi.org/10.1016/j.vaccine.2007.06.017
_version_ 1783514110453874688
author Hu, Mary C.
Jones, Taff
Kenney, Richard T.
Barnard, Dale L.
Burt, David S.
Lowell, George H.
author_facet Hu, Mary C.
Jones, Taff
Kenney, Richard T.
Barnard, Dale L.
Burt, David S.
Lowell, George H.
author_sort Hu, Mary C.
collection PubMed
description The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice.
format Online
Article
Text
id pubmed-7115497
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71154972020-04-02 Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice Hu, Mary C. Jones, Taff Kenney, Richard T. Barnard, Dale L. Burt, David S. Lowell, George H. Vaccine Article The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice. Elsevier Ltd. 2007-08-21 2007-06-29 /pmc/articles/PMC7115497/ /pubmed/17640780 http://dx.doi.org/10.1016/j.vaccine.2007.06.017 Text en Copyright © 2007 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hu, Mary C.
Jones, Taff
Kenney, Richard T.
Barnard, Dale L.
Burt, David S.
Lowell, George H.
Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
title Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
title_full Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
title_fullStr Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
title_full_unstemmed Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
title_short Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
title_sort intranasal protollin-formulated recombinant sars s-protein elicits respiratory and serum neutralizing antibodies and protection in mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115497/
https://www.ncbi.nlm.nih.gov/pubmed/17640780
http://dx.doi.org/10.1016/j.vaccine.2007.06.017
work_keys_str_mv AT humaryc intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice
AT jonestaff intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice
AT kenneyrichardt intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice
AT barnarddalel intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice
AT burtdavids intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice
AT lowellgeorgeh intranasalprotollinformulatedrecombinantsarssproteinelicitsrespiratoryandserumneutralizingantibodiesandprotectioninmice